VANCOUVER, BRITISH COLUMBIA — March 5, 2026 — Leads & Copy — Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a Canadian biopharmaceutical company, announced that its CEO, Dr. Frederick D. Sancilio, will be in Miami, Florida, during the upcoming Jefferies and Leerink Healthcare Conferences.
Dr. Sancilio will be available for meetings with investors, pharmaceutical companies, and other organizations interested in learning more about Lobe and its programs.
Lobe acquires preclinical and early-stage therapeutic assets and places them within focused subsidiary entities. Each program follows a defined development and funding structure designed to support advancement through regulatory and clinical milestones.
The company’s approach includes formulation development, intellectual property protection, and engagement with regulatory authorities as programs advance through clinical evaluation and value-inflection points in a cost-efficient manner.
Lobe is currently advancing two patented assets through this subsidiary approach: L‑130, targeting chronic cluster headache, and S‑100, focused on sickle cell disease. Additional programs under evaluation include therapies for substance use disorder and other neurological indications.
Organizations interested in arranging a meeting with Dr. Sancilio while he is in Miami may contact the Company by email at partnerships@lobesciences.com to schedule an appointment.
Lobe Sciences Ltd. is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Applied Lipid Technologies, Inc. (formerly Altemia, Inc.).
Cynaptec is focused on the use of its proprietary L‑130 (psilocin mucate) compound for treatment of chronic cluster headache, and is also assessing potential utility for substance use disorders. Lobe owns 64% of Cynaptec.
L‑130 is a novel, patented, oral, stable analog of psilocin, designed to enhance bioavailability and therapeutic efficacy.
Source: Lobe Sciences Ltd.
